According to a recent LinkedIn post from Brevel Ltd, the company is highlighting Purallis™, a chlorella-based powder ingredient positioned as a high-protein, nutrient-dense option for food and beverage formulations. The post describes a 50% protein content with a full amino acid profile, B vitamins, omega-3 fatty acids, iron, fiber, antioxidants, and chlorophyll, emphasizing a clean label positioning.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that Purallis™ is produced indoors in sterile bioreactors using Brevel’s patented “illuminated fermentation” technology, which is presented as a differentiator from pond-grown algae. The post suggests this method aims to avoid contamination and heavy metals while maintaining consistent nutritional composition batch to batch, potentially appealing to formulators seeking reliability and safety.
According to the post, Purallis™ is being marketed toward segments such as sports nutrition, healthy aging, and functional beverages, and is described as “GLP-1 friendly” for consumers pursuing higher nutrition with fewer calories. This targeting suggests a focus on growth categories aligned with weight-management drugs and performance nutrition, areas that have attracted strong investor interest in recent years.
If Brevel can secure adoption of Purallis™ by formulators and brands in these segments, the product could support recurring B2B revenue streams based on ingredient sales. The use of proprietary production technology may also strengthen Brevel’s competitive moat in the alternative protein and functional ingredient space, though actual financial impact will depend on scale-up, regulatory acceptance, and customer conversion not detailed in the post.